FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a method of treating hypertension, congestive cardiac failure, stenocardia, myocardial infarction, atherosclerosis, stroke. A method of treating involves introduction to a patient requiring such treatment of the solid oral dosage form containing a therapeutically effective amount of aliskiren or its pharmaceutically acceptable salt in which the active ingredient makes more than 46 wt % of total weight of the oral dosage form. The oral dosage form is presented in the form of a tablet or a film-coated tablet and produced by methods other than wet granulation with excipients by means of water and/or a water solution of a binding agent.
EFFECT: realisation of the specified purpose.
12 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2005 |
|
RU2384328C2 |
| ORAL SOLID DOSAGE FORM AND METHOD OF TREATING | 2011 |
|
RU2480210C1 |
| GALENA COMPOSITION OF ALISKIREN AND HYDROCHLOROTHIAZIDE | 2007 |
|
RU2491058C2 |
| GALENIC FORMULATIONS OF ALISKIREN | 2008 |
|
RU2483718C2 |
| GALENICAL PREPARATIONS OF ORGANIC COMPOUNDS | 2010 |
|
RU2535090C2 |
| ADMINISTRATION OF RENIN INHIBITORS FOR PREVENTION OR TREATMENT OF DIASTOLIC DYSFUNCTION OR DIASTOLIC HEART FAILURE | 2005 |
|
RU2407523C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING COMBINATION OF VILDAGLIPTIN AND GLIQUIDONE | 2014 |
|
RU2585378C1 |
| ESCITALOPRAM AND HARD PHARMACETICAL COMPOSITION CONTAINING IT | 2007 |
|
RU2463039C2 |
| NEW COMPOSITION | 2006 |
|
RU2821230C2 |
